
Maria José Mellado Peña

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10174545/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prevalence of nonalcoholic fatty liver disease using noninvasive techniques among children, adolescents, and youths living with HIV. Aids, 2022, 36, 805-814.	2.2	7
2	Targeting the Gut Microbiota of Vertically HIV-Infected Children to Decrease Inflammation and Immunoactivation: A Pilot Clinical Trial. Nutrients, 2022, 14, 992.	4.1	6
3	Screening for parasites in migrant children. Travel Medicine and Infectious Disease, 2022, 47, 102287.	3.0	5
4	Eosinophilia in Migrant Children. Pediatric Infectious Disease Journal, 2022, 41, 102-107.	2.0	2
5	ls there autochthonous strongyloidiasis in Spanish children?. European Journal of Pediatrics, 2021, 180, 1641-1645.	2.7	2
6	The Issue of Body Mass Index Increase in Adolescents Living With HIV on ART. Pediatric Infectious Disease Journal, 2021, 40, e319-e321.	2.0	0
7	Handing over and satisfaction of a term leading the Spanish Association of Paediatrics. Anales De PediatrAa (English Edition), 2021, 94, 357-358.	0.2	0
8	Low COVID-19 mortality in Spanish children. The Lancet Child and Adolescent Health, 2021, 5, e24-e25.	5.6	12
9	Entrega y satisfacción de una legislatura al frente de la Asociación Española de PediatrÃa (AEP). Anales De PediatrÃa, 2021, 94, 357-358.	0.2	2
10	Human Microbiome in Children, at the Crossroad of Social Determinants of Health and Personalized Medicine. Children, 2021, 8, 1191.	1.5	2
11	Effect of Hepatitis C Virus Coinfection on the Progression of Vertically Acquired Human Immunodeficiency Virus Infection During Childhood and Adolescence. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 232-235.	1.3	Ο
12	Longitudinal evolution of vertically HIV/HCV–coâ€infected vs HCV–monoâ€infected children. Journal of Viral Hepatitis, 2020, 27, 61-67.	2.0	6
13	Effect of a Nutritional Intervention on the Intestinal Microbiota of Vertically HIV-Infected Children: The Pediabiota Study. Nutrients, 2020, 12, 2112.	4.1	10
14	Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study. AIDS Research and Therapy, 2020, 17, 45.	1.7	1
15	Ten key points about COVIDâ€19 in children: The shadows on the wall. Pediatric Pulmonology, 2020, 55, 2576-2586.	2.0	20
16	Combined treatment with immunoglobulin and valaciclovir in pregnant women with cytomegalovirus infection and high risk of symptomatic fetal disease. Journal of Maternal-Fetal and Neonatal Medicine, 2020, , 1-5.	1.5	4
17	Diagnostic Accuracy of QuantiFERON-TB Gold Plus Assays in Children and Adolescents with Tuberculosis Disease. Journal of Pediatrics, 2020, 223, 212-215.e1.	1.8	14
18	Prognostic factors of a lower CD4/CD8 ratio in long term viral suppression HIV infected children. PLoS ONE, 2019, 14, e0220552.	2.5	5

#	Article	IF	CITATIONS
19	Sociodemographic changes and trends in the rates of new perinatal HIV diagnoses and transmission in Spain from 1997 to 2015. PLoS ONE, 2019, 14, e0223536.	2.5	6
20	Early and Highly Suppressive Antiretroviral Therapy Are Main Factors Associated With Low Viral Reservoir in European Perinatally HIV-Infected Children. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 269-276.	2.1	57
21	Sleep Profile and Self-Reported Neuropsychiatric Symptoms in Vertically HIV-Infected Adolescents on cART. Journal of Pediatric Infectious Diseases, 2018, 13, 300-307.	0.2	6
22	Tuberculosis en lactantes menores de 3 meses. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 243-245.	0.5	6
23	Réplica a «Tuberculosis en lactantes menores de 3 meses de Risaralda, Colombia». Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 328-329.	0.5	0
24	New diagnoses of human immunodeficiency virus infection in the Spanish pediatric HIV Cohort (CoRISpe) from 2004 to 2013. Medicine (United States), 2017, 96, e7858.	1.0	7
25	Low Bone Mineral Density in Vertically HIV-infected Children and Adolescents. Pediatric Infectious Disease Journal, 2017, 36, 578-583.	2.0	17
26	Pregnancy outcomes in perinatally HIV-infected young women in Madrid, Spain: 2000-2015. PLoS ONE, 2017, 12, e0183558.	2.5	13
27	Unsuspected Congenital Tuberculosis. Pediatric Infectious Disease Journal, 2016, 35, 225.	2.0	4
28	Clinical Features Before Hematopoietic Stem Cell Transplantation or Enzyme Replacement Therapy of Children With Combined Immunodeficiency. Pediatric Infectious Disease Journal, 2016, 35, 794-798.	2.0	4
29	Immunisation practices in centres caring for children with perinatally acquired HIV: A call for harmonisation. Vaccine, 2016, 34, 5587-5594.	3.8	2
30	Prevalence of Elevated Blood Pressure in HIV-infected Children, Adolescents and Young Adults. Pediatric Infectious Disease Journal, 2016, 35, 824-825.	2.0	3
31	Disease disclosure, treatment adherence, and behavioural profile in a cohort of vertically acquired HIV-infected adolescents. NeuroCoRISpeS study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 124-130.	1.2	25
32	Cardiac Function in Vertically HIV-infected Children and Adolescents in the Era of Highly Active Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2015, 34, e125-e131.	2.0	16
33	Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults. BMC Infectious Diseases, 2015, 15, 119.	2.9	33
34	Establishment and Replenishment of the Viral Reservoir in Perinatally HIV-1-infected Children Initiating Very Early Antiretroviral Therapy. Clinical Infectious Diseases, 2015, 61, 1169-1178.	5.8	97
35	Determinants of Highly Active Antiretroviral Therapy Duration in HIV-1-Infected Children and Adolescents in Madrid, Spain, from 1996 to 2012. PLoS ONE, 2014, 9, e96307.	2.5	7
36	Subclinical Atherosclerosis and Markers of Immune Activation in HIV-Infected Children and Adolescents. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 42-49.	2.1	53

Maria José Mellado Peña

#	Article	IF	CITATIONS
37	Cardiovascular biomarkers in vertically HIV-infected children without metabolic abnormalities. Atherosclerosis, 2014, 233, 410-414.	0.8	20
38	Effect of Nutritional Status on Tuberculin Skin Testing. Indian Journal of Pediatrics, 2013, 80, 271-275.	0.8	6
39	Adherence to Antiretroviral Therapy and Acceptability of Planned Treatment Interruptions in HIV-Infected Children. AIDS and Behavior, 2013, 17, 193-202.	2.7	6
40	Author response to Tebruegge, et al. Archives of Disease in Childhood, 2013, 98, 240-241.	1.9	0
41	The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults. Aids, 2013, 27, 1513-1516.	2.2	125
42	Implementation of Occult Hepatitis Screening in the Spanish Cohort of HIV-infected Pediatric Patients. Pediatric Infectious Disease Journal, 2013, 32, e377-e379.	2.0	8
43	Trends in Drug Resistance Prevalence in HIV-1–infected Children in Madrid. Pediatric Infectious Disease Journal, 2012, 31, e213-e221.	2.0	16
44	Interferon-Î ³ release assay for the diagnosis of tuberculosis in children. Archives of Disease in Childhood, 2012, 97, 514-516.	1.9	14
45	Is there interference in the interpretation of the tuberculin skin test in children with intestinal parasitic infestation?. Pathogens and Global Health, 2012, 106, 172-176.	2.3	7
46	Tuberculin skin test in bacille Calmette–Guérin-vaccinated children: how should we interpret the results?. European Journal of Pediatrics, 2012, 171, 1625-1632.	2.7	28
47	High Drug Resistance Prevalence among Vertically HIV-Infected Patients Transferred from Pediatric Care to Adult Units in Spain. PLoS ONE, 2012, 7, e52155.	2.5	31
48	HIV-Infected Adolescents: Relationship Between Atazanavir Plasma Levels and Bilirubin Concentrations. Journal of Adolescent Health, 2011, 48, 100-102.	2.5	10
49	OPTIMIZING INTERPRETATION OF THE TUBERCULIN TEST USING AN INTERFERON-GAMMA RELEASE ASSAY AS A REFERENCE STANDARD. Pediatric Infectious Disease Journal, 2011, 30, 426-428.	2.0	14
50	Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain. Journal of Antimicrobial Chemotherapy, 2011, 66, 2362-2371.	3.0	17
51	Lack of Sensitivity of QuantiFERON-TB Gold Test in Tube in a Child With Tuberculous Meningitis. Pediatric Infectious Disease Journal, 2010, 29, 683-684.	2.0	4
52	Impact of Highly Active Antiretroviral Therapy (HAART) on AIDS and Death in a Cohort of Vertically HIV Type 1-Infected Children: 1980–2006. AIDS Research and Human Retroviruses, 2009, 25, 1091-1097.	1.1	26
53	PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIVâ€1 infection. HIV Medicine, 2009, 10, 591-613.	2.2	135
54	Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children. BMC Infectious Diseases, 2006, 6, 107.	2.9	8

#	Article	IF	CITATIONS
55	Safety and Antiviral Response at 12 Months of Lopinavir/Ritonavir Therapy in Human Immunodeficiency Virus-1-Infected Children Experienced With Three Classes of Antiretrovirals. Pediatric Infectious Disease Journal, 2005, 24, 867-873.	2.0	24
56	Viral phenotype, antiretroviral resistance and clinical evolution in human immunodeficiency virus-infected children. Pediatric Infectious Disease Journal, 1997, 16, 1032-1037.	2.0	3
57	Nutritional Supplementation to Increase Influenza Vaccine Response in Children Living With HIV: A Pilot Clinical Trial. Frontiers in Pediatrics, 0, 10, .	1.9	ο